Revisiting the bioavailability of flavan-3-ols in humans: A systematic review and comprehensive data analysis

dc.contributor.authorDi Pede, Giuseppe
dc.contributor.authorMena, Pedro
dc.contributor.authorBresciani, Letizia
dc.contributor.authorAchour, Mariem
dc.contributor.authorLamuela Raventós, Rosa Ma.
dc.contributor.authorEstruch Riba, Ramon
dc.contributor.authorLandberg, Rikard
dc.contributor.authorKulling, Sabine
dc.contributor.authorWishart, David S.
dc.contributor.authorRodríguez-Mateos, Ana
dc.contributor.authorCrozier, Alan
dc.contributor.authorManach, Claudine
dc.contributor.authorDel Rio, Daniele
dc.date.accessioned2023-02-23T10:18:27Z
dc.date.available2023-02-23T10:18:27Z
dc.date.issued2023-02-01
dc.date.updated2023-02-23T10:18:27Z
dc.description.abstractThis systematic review summarizes findings from human studies investigating the different routes of absorption, metabolism, distribution and excretion (ADME) of dietary flavan-3-ols and their circulating metabolites in healthy subjects. Literature searches were performed in PubMed, Scopus and the Web of Science. Human intervention studies using single and/or multiple intake of flavan-3-ols from food, extracts, and pure compounds were included. Forty-nine human intervention studies met inclusion criteria. Up to 180 metabolites were quantified from blood and urine samples following intake of flavan-3-ols, mainly as phase 2 conjugates of microbial catabolites (n =97), with phenyl-γ-valerolactones being the most representative ones (n =34). Phase 2 conjugates of monomers and phenyl-γ-valerolactones, the main compounds in both plasma and urine, reached two peak plasma concentrations (Cmax) of 260 and 88 nmol/L at 1.8 and 5.3 h (Tmax) after flavan-3-ol intake. They contributed to the bioavailability of flavan-3-ols for over 20%. Mean bioavailability for flavan-3-ols was moderate (31 ±23%, n bioavailability values =20), and it seems to be scarcely affected by the amount of ingested compounds. While intra- and inter-source differences in flavan-3-ol bioavailability emerged, mean flavan-3-ol bioavailability was 82% (n =1) and 63% (n =2) after ()-epicatechin and nut (hazelnuts, almonds) intake, respectively, followed by 25% after consumption of tea (n =7), cocoa (n =5), apples (n =3) and grape (n =2). This highlights the need to better clarify the metabolic yield with which monomer flavan-3-ols and proanthocyanidins are metabolized in humans. This work clarified in a comprehensive way for the first time the ADME of a (poly)phenol family, highlighting the pool of circulating compounds that might be determinants of the putative beneficial effects linked to flavan-3-ol intake. Lastly, methodological inputs for implementing well- designed human and experimental model studies were provided.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec729945
dc.identifier.issn0098-2997
dc.identifier.urihttps://hdl.handle.net/2445/194013
dc.language.isoeng
dc.publisherElsevier Ltd
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.mam.2022.101146
dc.relation.ispartofMolecular Aspects of Medicine, 2023, vol. 89
dc.relation.urihttps://doi.org/10.1016/j.mam.2022.101146
dc.rightscc-by-nc-nd (c) Giuseppe Di Pede, et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
dc.subject.classificationCompostos bioactius
dc.subject.classificationFlavonoides
dc.subject.otherBioactive compounds
dc.subject.otherFlavonoids
dc.titleRevisiting the bioavailability of flavan-3-ols in humans: A systematic review and comprehensive data analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
729945.pdf
Mida:
5.47 MB
Format:
Adobe Portable Document Format